I-Mab announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug application to initiate a phase Ib trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus.
[I-Mab]
7992332
{7992332:nan}
apa
50
1
163929
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
